Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
Sahil Khanna(Mayo Clinic), Paul Feuerstadt(Gastroenterology Center of Connecticut), Scott Berry(Queen's University), Thomas Louie(Alberta Health Services), Gary P. Wang(University of Florida), David Yoho(Kaiser Permanente), Tricia Braun, Julia Garcia‐Diaz(Ochsner Medical Center), Joe Marion(Berry & Associates (United States)), Christine Lee(University of Victoria), Xin Su(Chongqing Medical University), Maha Assi(University of Kansas), W Knapple(Arkansas Department of Agriculture), Humberto Aguilar, Lindy Bancke
Cited by 6
Related Papers
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k
Fidaxomicin versus Vancomycin for <i>Clostridium difficile</i> Infection
|New England Journal of Medicine|2011|1.6k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k